CG Oncology (CG Oncology) YoY EBITDA Growth : 77.81% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CG Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 77.81%.

CG Oncology's EBITDA per Share for the three months ended in Mar. 2024 was $-0.48.

CG Oncology YoY EBITDA Growth Historical Data

The historical data trend for CG Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology YoY EBITDA Growth Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

YoY EBITDA Growth

-2,466.21

-35.90

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial			-	-	-	-	77.81

CG Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CG Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-12.799	-	-9.418)	/	\| -9.418 \|
=	-35.90 %

CG Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.477	-	-2.15)	/	\| -2.15 \|
=	77.81 %

CG Oncology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of CG Oncology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024